ArticleJournal of experimental & clinical cancer research : CR2010
Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines.
Article in Journal of experimental & clinical cancer research : CR, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Taurultam shows antiviral activity against SARS-CoV-2 and influenza virus.BMC microbiology · 2025Article
- Mechanism and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer.Cancer medicine · 2024Article
- Exploring the effects of taurolidine on tumor weight and microvessel density in a murine model of osteosarcoma.Oncology research · 2024Article
- Dual functionality of the antimicrobial agent taurolidine which demonstrates effective anti-tumor properties in pediatric neuroblastoma.Investigational new drugs · 2020Article
- Article
- Short-term treatment with taurolidine is associated with liver injury.BMC pharmacology & toxicology · 2017Article
- Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo.BMC cancer · 2017Article
- Evaluation of the safety and efficacy of TRAIL and taurolidine use on human fibrosarcoma xenograftsOncology letters · 2016Article
- Taurolidine induces epithelial-mesenchymal transition via up-regulation of the transcription factor Snail in human pancreatic cancer cell lines.International journal of colorectal disease · 2014Article
- Taurolidine cooperates with antineoplastic drugs in neuroblastoma cells.Genes & cancer · 2014Article
- Redox-directed cancer therapeutics: Taurolidine and Piperlongumine as broadly effective antineoplastic agents (review).International journal of oncology · 2014Review
- Antineoplastic activity of povidone-iodine on different mesothelioma cell lines: results of in vitro study.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2014Article
- The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro.BMC veterinary research · 2013Article
- Antibacterial effect of taurolidine (2%) on established dental plaque biofilm.Clinical oral investigations · 2012Article
- Gene expression analysis of cell death induction by taurolidine in different malignant cell lines.BMC cancer · 2010Article
- Oral administration of the anti-proliferative substance taurolidine has no impact on dextran sulfate sodium induced colitis-associated carcinogenesis in mice.Journal of carcinogenesis · 2010Article
- The Antiseptic and Antineoplastic Agent Taurolidine Modulates Key Leukocyte Functions.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTaurolidine (TRD) represents an anti-infective substance with anti-neoplastic activity in many malignant cell lines. So far, the knowledge about the cell death inducing mechanisms and pathways activated by TRD is limited. The aim of this study was therefore, to perform a comparative analysis of cell death induction by TRD simultaneously in different malignant cell lines. MATERIALS AND
methodsFive different malignant cell lines (HT29/Colon, Chang Liver/Liver, HT1080/fibrosarcoma, AsPC-1/pancreas and BxPC-3/pancreas) were incubated with increasing concentrations of TRD (100 microM, 250 microM and 1000 microM) for 6 h and 24 h. Cell viability, apoptosis and necrosis were analyzed by FACS analysis (Propidiumiodide/AnnexinV staining). Additionally, cells were co-incubated with the caspase Inhibitor z-VAD, the radical scavenger N-Acetylcystein (NAC) and the Gluthation depleting agent BSO to examine the contribution of caspase activation and reactive oxygen species in TRD induced cell death.
resultsAll cell lines were susceptible to TRD induced cell death without resistance toward this anti-neoplastic agent. However, the dose response effects were varying largely between different cell lines. The effect of NAC and BSO co-treatment were highly different among cell lines--suggesting a cell line specific involvement of ROS in TRD induced cell death. Furthermore, impact of z-VAD mediated inhibition of caspases was differing strongly among the cell lines.
conclusionThis is the first study providing a simultaneous evaluation of the anti-neoplastic action of TRD across several malignant cell lines. The involvement of ROS and caspase activation was highly variable among the five cell lines, although all were susceptible to TRD induced cell death. Our results indicate, that TRD is likely to provide multifaceted cell death mechanisms leading to a cell line specific diversity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.